Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
Sponsor: Eli Lilly and Company
Summary
The purpose of this study is to evaluate how well LY4057996 is tolerated and what side effects may occur in healthy participants and participants with Type 1 and Type 2 Diabetes. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4057996 gets into the bloodstream and how long it takes the body to eliminate it. The study will last 11 weeks for Part A1-A2, 4 weeks for A3-A5, 6 weeks for Part B and 7 weeks for Part C, all approximations, excluding a screening period.
Official title: A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
124
Start Date
2025-05-16
Completion Date
2026-12
Last Updated
2026-03-11
Healthy Volunteers
Yes
Interventions
LY4057996 SC
Administered SC
LY4057996 IV
Administered IV
Placebo SC
Administered SC
Placebo IV
Administered IV
Degludec SC
Administered SC
Lispro SC
Administered SC
Degludec IV
Administered IV
Pre-study basal insulin SC
Administered SC
Locations (1)
Profil Institut für Stoffwechselforschung
Neuss, Germany